What are the potential benefits of Octreotide?

FDA-approved for acromegaly (GH excess) management. FDA-approved for carcinoid tumor flushing and diarrhea. FDA-approved for VIPoma-associated diarrhea. Reduces splanchnic blood flow for GI bleeding. Long-acting depot formulation (Sandostatin LAR) for monthly dosing. Antiproliferative effects in neuroendocrine tumors. Neuroprotective potential via neuronal migration effects

What compounds work synergistically with Octreotide?

Octreotide has been studied alongside Lanreotide, Pasireotide, Interferon-alpha for potential synergistic effects.

Octreotide — Mechanism, Benefits, Research & Synergies

Overview

Octreotide is a synthetic octapeptide analog of somatostatin with markedly extended half-life (~2 hours IV vs 1-3 minutes for native somatostatin). FDA-approved for acromegaly (excess GH) and symptomatic treatment of metastatic carcinoid tumors and VIPomas, it is one of the most clinically important peptide drugs in medicine. It mimics the inhibitory effects of endogenous somatostatin on growth hormone, glucagon, and gastrointestinal hormones while also causing vascular smooth muscle contraction to reduce splanchnic blood flow.

Mechanism of Action

Octreotide binds somatostatin receptors (primarily SSTR2 and SSTR5), which are GPCRs coupled to inhibitory G-proteins. Activation inhibits adenylyl cyclase (reducing cAMP), stimulates phospholipase C via beta-gamma G-protein subunits, leads to calcium channel inhibition and K+ channel activation, ultimately suppressing GH, IGF-1, insulin, glucagon, and various gastrointestinal hormones. In neuroendocrine tumors, SSTR2 binding drives CDKN1B (p27) upregulation inhibiting cell proliferation. Also stimulates neuronal migration and axon outgrowth.

Potential Benefits

FDA-approved for acromegaly (GH excess) management
FDA-approved for carcinoid tumor flushing and diarrhea
FDA-approved for VIPoma-associated diarrhea
Reduces splanchnic blood flow for GI bleeding
Long-acting depot formulation (Sandostatin LAR) for monthly dosing
Antiproliferative effects in neuroendocrine tumors
Neuroprotective potential via neuronal migration effects

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

Acromegaly: 50-600 mcg/day subcutaneously in divided doses. Carcinoid: 100-600 mcg/day. Long-acting depot (LAR): 20-40 mg IM monthly.

Amino Acid Sequence

D-Phe-cyclo[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr-ol (disulfide bridge Cys2-Cys7)

Side Effects & Safety

GI symptoms: nausea, diarrhea, abdominal cramping, steatorrhea
Cholelithiasis (gallstone formation) with long-term use
Bradycardia
Hypoglycemia or hyperglycemia
Injection site pain
Hypothyroidism with prolonged use

Synergistic Compounds

The following compounds have been studied alongside Octreotide for potential complementary or synergistic effects:

LanreotidePasireotideInterferon-alpha

Learn More

Beginner's GuideNew to peptides? Start here Stacking GuideSynergistic combinations Administration RoutesSubQ, IM, oral, nasal & more Reconstitution CalculatorCalculate exact dosing Peptides vs SARMsFull comparison How Peptides Are MadeSPPS, purification & QC

References & Further Reading

[object Object]
[object Object]

Quick Facts

Molecular Weight	1019.24 g/mol
Research Status	Well-established FDA-approved drug. Extensive clinical literature across multiple indications. Active research in neuroendocrine tumors, thyroid disorders, and neurological applications.

More Peptides in This Category

BPC-157 TB-500 GHRP-6 Hexarelin GHK-Cu Follistatin-344

Octreotide